SCOTT D. MYERS has served as our president, chief executive officer and director since April 4, 2016. Prior to joining Cascadian Therapeutics, Mr. Myers served as the chief executive officer of Aerocrine AB, a life sciences company, from September 2011 until it was acquired by Circassia Pharmaceuticals plc in July 2015. From January 2007 to August 2011, Mr. Myers served as a vice president of UCB S.A., a biopharmaceutical company. In this role, Mr. Myers oversaw commercial operations and medical affairs for 32 countries in Europe. From December 2005 to January 2007, Mr. Myers served as the chief commercial officer for DOV Pharmaceutical, a development stage pharmaceutical company, and from 2000 to 2005, Mr. Myers held several senior positions at Johnson & Johnson, including senior vice president and general manager. Additionally, from April 2012 to April 2014, Mr. Myers served as a member of the board of directors of Orexo AB, a pharmaceutical company and is currently an Industry Advisor for EQT, an investment fund. Mr. Myers received his B.A. in biology from Northwestern University and M.B.A from the Graduate School of Business from the University of Chicago.
GARY W. CHRISTIANSON has served as our chief operating officer since July 2007. From 2005 to 2007, Mr. Christianson was site director for the Biologics Unit of GlaxoSmithKline plc, a global healthcare company. From 1999 to 2003, Mr. Christianson was vice president, technical operations at Corixa Corp., a biopharmaceutical and biotechnology company, and from 2003 to 2005, he was general manager of the Hamilton, Montana site in addition to his duties as vice president. From 1987 to 1999, Mr. Christianson held various positions at RIBI ImmunoChem Research, a biopharmaceuticals company. Mr. Christianson received a B.S. in mechanical engineering technology from Montana State University.
GUY F. CIPRIANI has served as our vice president, business development since July 2012. Prior to that, he served as chief business officer for Immune Design Corp, a privately held biotechnology company. From 2005 to November 2011 he served as vice president, business development for Cardiome Pharmaceuticals, a publicly traded biotechnology company. At Cardiome, Mr. Cipriani directed the out-licensing of Cardiome's Phase 3 product candidate to Merck & Company and in-licensed multiple product candidates. Prior to Cardiome, Mr. Cipriani worked as senior director, business development for Transform Pharmaceutical, Inc., a biotechnology company acquired by Johnson & Johnson in April 2005, and in corporate business development for five years at Eli Lilly and Company. Mr. Cipriani received an M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. in electrical engineering from Rochester Institute of Technology.
JULIE M. EASTLAND has served as our chief financial officer and vice president, corporate development since August 2010. From 2006 to August 2010, Ms. Eastland served as chief financial officer and vice president finance and operations of VLST Corporation. From 2000 to 2005, Ms. Eastland held various finance positions at Dendreon Corporation, most recently as the vice president of strategic planning. Prior to Dendreon, Ms. Eastland worked for Amgen, Inc. as area finance manager and assistant controller for its Colorado operations. Ms. Eastland has also worked as director of finance and planning for Encore Media Group, international finance and business manager and senior financial analyst for SCIENCE Magazine and financial manager for the Discovery Channel. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.
MONIQUE GREER has served as our senior vice president, investor relations and corporate communications since October 2016. Ms. Greer has an extensive background in developing innovative approaches that advance communications in corporate positioning, issues management, patient advocacy, commercialization and investor relations. She has played an active role in several successful financing rounds and helped launch multiple drugs in the U.S. and Europe. From 2012 to October 2016, Ms. Greer served as senior vice president, corporate communications and investor relations at CTI BioPharma Corp., where she led the company's corporate communications, investor relations, advocacy relations and product communications. Ms. Greer has served in similar senior communications roles at Allos Therapeutics, Inc. (acquired by Spectrum Pharmaceuticals); WCG, a global communications agency; Dendreon Corporation and Heska Corporation. Ms. Greer received a B.S. in marketing and international business from Northeastern University in Boston.
MARC L. LESNICK, Ph.D. has served as our senior vice president, regulatory affairs and quality since January 2017. Dr. Lesnick was most recently senior vice president, U.S. Regulatory Affairs, Global Development Projects at Shionogi, Inc., the U.S. subsidiary of Shionogi & Co., Ltd., where he was responsible for regulatory strategy for an early stage dual-tyrosine kinase inhibitor program for HER2-positive breast cancer, led the filing of a new drug application for opioid induced constipation and oversaw approval and launch of a drug in the field of women's health. In this role, Dr. Lesnick had oversight of regulatory strategy, regulatory operations, drug safety and medical writing. In his prior role at Optimer Pharmaceuticals, he led the approval of a new antibiotic for the treatment of C. dificile infections in the US and EU. Dr. Lesnick held similar positions at Verus Pharmaceuticals and PAREXEL International. Dr. Lesnick received his Ph.D. from the University of Oregon, and continued his post-doctoral studies at the University of California, San Diego, School of Medicine.
SCOTT R. PETERSON, Ph.D. has served as our chief scientific officer since June 2012. From 2009 until June 2012, Dr. Peterson served as our vice president, research and development, and from 2007 until 2009, Dr. Peterson was director of oncology research at ZymoGenetics. Prior to that, Dr. Peterson was a principal scientist at ICOS Corporation where he led both small molecule and antibody cancer drug discovery programs. Dr. Peterson has a Ph. D. in chemistry from the University of Colorado, Boulder and a B.S. in biology from Washington State University.
LUKE N. WALKER, M.D. has served as our vice president, clinical development since May 2016 and held positions of senior director, clinical research and director, clinical research since joining the company in September 2011. Prior to that, Dr. Walker served as a medical oncologist and hematologist at Providence Regional Medical Center, Everett from 2007 to 2011 and at The Everett Clinic, Center for Cancer Care from 2005 to 2007. Dr. Walker completed fellowships in bone marrow and stem cell transplantation and hematology and medical oncology at Oregon Health Sciences University and received an M.D. from University of Oklahoma Health Sciences Center. He received a B.A. in letters and French from the University of Oklahoma.